Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers

Rolf Dario Frank; Björn Altenwerth; Vincent M. Brandenburg; Martina Nolden-Koch; Frank Block

doi:10.1055/s-0037-1614776

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2005; 94(02): 466-468
DOI: 10.1055/s-0037-1614776

Letters to the Editor

Schattauer GmbH

Effect of intravenous high-dose methylprednisolone on coagulation and fibrinolysis markers

Rolf Dario Frank

¹Department of Nephrology and Clinical Immunology, Aachen, Germany

,

Björn Altenwerth

¹Department of Nephrology and Clinical Immunology, Aachen, Germany

,

Vincent M. Brandenburg

¹Department of Nephrology and Clinical Immunology, Aachen, Germany

,

Martina Nolden-Koch

²Departmentof Neurology, University Hospital Aachen, Aachen, Germany

,

Frank Block^*

²Departmentof Neurology, University Hospital Aachen, Aachen, Germany

› Author Affiliations

Abstract

Full Text

References

References
1 Cosgriff SW. Thromboembolic complications associated with ACTH and cortisone therapy. JAMA 1951; 147: 924-6.
2 Sjöberg HE, Blombäck M, Granberg PO. Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing`s syndrome. Acta Med Scand 1976; 199: 95-8.
3 Wadman B, Werner I. Thromboembolic complications during corticosteroid treatment of temporal arteritis. Lancet 1972; i: 907.
4 Albucher JF, Vuillemin-Azais C, Manelfe C. et al. Cerebral thrombophlebitis in three patients with probable multiple sclerosis. Cerebrovasc Dis 1999; 9: 298-303.
5 Stolz E, Klötzsch C, Schlachetzki F. et al. Highdose corticosteroid treatment is associated with an increased risk of developing cerebral venous thrombosis. Eur Neurol 2003; 49: 247-8.
6 Drescher W, Weigert KP, Bunger MH. et al. Femoral head blood flow reduction and hypercoagulability under 24 h megadose steroid treatment in pigs. J Orthoped Res 2004; 22: 501-8.
7 McDonald WI, Compston A, Edan G. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
8 Fatti LM, Bottasso B, Invitti C. et al. Markers of activation of coagulation and fibrinolysis in patients with Cushing´s syndrome. J Endocrinol Invest 2000; 23: 145-50.
9 Patrassi GM, Sartori MT, Viero ML. et al. The fibrinolytic potential in patients with Cushing´s disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 789-93.
10 Vandenberghe N, Debouverie M, Anxionnat R. et al. Cerebral venous thrombosis in four patients with multiple sclerosis. Eur J Neurol 2003; 10: 63-6.
11 Oner AF, Gurgey A, Kirazli S. et al. Changes of hemostatic factors in children with acute lymphoblastic leukemia receiving combined chemotherapy including high dose methylprednisolone and L-asparaginase. Leuk Lymphoma 1999; 33: 361-4.
12 Mall V, Thomas KB, Sauter S. et al. Effect of glucocorticoids, E.coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia. Klin Padiatr 1999; 211: 205-10.
13 Sevaljevic L, Macvanin M, Zakula Z. et al. Adrenalectomy and dexamethasone treatment alter the patterns of basal and acute phase response-induced expression of acute phase protein genes in rat liver. J Steroid Biochem Mol Biol 1998; 66: 347-53.
14 Kraaijenhagen RA, in't Anker PS, Koopman MMW. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
15 Koster T, Blann AW, Briet E. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995; 345: 152-5.
16 Patrassi GM, Sartori MT, Livi U. et al. Impairment of fibrinolytic potential in long-term steroid treatment after heart transplantation. Transplantation 1997; 64: 1610-13.